Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia

Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud0 个研究点目标入组 26 人开始时间: 2020年4月27日最近更新: 2020年5月4日

试验速览

暂无简介。

•1. Age = 18
•2. Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection
•3. Life expectancy > 48 hours.
•4. Commitment to use a contraceptive method of proven efficacy in both men and women during the duration of the clinical trial.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 26
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 26

•1. Coinfection with other viruses or bacteria (HIV, tuberculosis, influenza virus, adenovirus or other respiratory infections, active infection by HBV or C).
•2. History of multiple allergies, including allergy to Penicillin or other B-lactams.
•3. Pregnant and lactating women.
•4. Patients with malignant tumors or hemopathies or any state of immunosuppression considered as severe.
•5. Patients with autoimmune diseases.
•6. Chronic heart failure with ejection fraction less than 30%.
•7. Any other condition for which, in the opinion of the main investigator, the subject is considered not to be in compliance with the study.

发起方

Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud